HOME >> MEDICINE >> NEWS
Pitt transplant researchers say anti-rejection drug rapamycin may help lupus, some cancers

PITTSBURGH, Jan. 22 Rapamycin, a drug approved for use in kidney transplant patients to prevent organ rejection, could also benefit patients with lupus and other autoimmune diseases as well as patients with blood cancers, such as acute myeloid leukemia, reports a team of researchers from the University of Pittsburgh's Thomas E. Starzl Transplantation Institute and Institute of Clinical Immunology and Transfusion Medicine, Justus-Liebig University in Giessen, Germany.

Their conclusions, outlined in a paper to be published in the journal Blood and currently posted on the journal's Web site (www.bloodjournal.org), were based on two key discoveries about rapamycin's mechanisms.

First, while rapamycin suppresses immune system T cells, as many anti-rejection drugs do, the researchers found that the drug also inhibits the function and activation of dendritic cells, cells that play a much earlier role in the immune response as the first cells to identify foreign intruders. They in turn present these intruders to other immune system cells, including T cells.

Second, and perhaps more surprising to the study's authors, rapamycin disarms the trigger that allows dendritic cells to proliferate. This trigger, a potent, naturally occurring growth factor, also affects the proliferation of blood precursor and stem cells, which if allowed to grow unchecked, result in leukemia and other cancers.

"Rapamycin's effect on dendritic cells impairs immune reactivity at the earliest stages. Because dendritic cells are important for the initiation and regulation of immune response, this effect is very important. Our findings provide novel insight into the pharmacology of this agent and have significant implications for the development of new therapeutic strategies in disease processes in which dendritic cells play a crucial immunopathological role," stated Angus W. Thomson, Ph.D., D.Sc., professor of surgery and immu
'"/>

Contact: Lisa Rossi
412-647-3555
University of Pittsburgh Medical Center
22-Jan-2003


Page: 1 2

Related medicine news :

1. Success of liver transplantation may be most influenced by three risk factors
2. Alcohol relapse adversely affects 10-year liver transplant survival
3. Donor age has no affect on long-term liver transplant survival
4. Age shouldnt be a factor in kidney transplantation
5. Cornea transplants can be improved
6. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
7. Hard choices: Pitt researcher presents findings on when to accept organ transplants
8. Biochemical marker aids prognosis in liver transplant patients
9. Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
10. Age should not be a factor in determining heart transplantation eligibility, researchers say
11. Study explores risks of obesity in children with kidney transplants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... organization behind the New England Journal of Medicine and NEJM Journal Watch, announces ... Pediatrics Board Review was created by a panel of pediatricians from leading medical ...
(Date:3/27/2017)... Orion, Michigan (PRWEB) , ... March 27, 2017 ... ... results. The comprehensive weight management program at Women’s Excellence will help patients ... initial evaluation and physical exam. The specialists at Women's Excellence will measure ...
(Date:3/27/2017)... ... ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from California ... she said. , She thinks the coming week is going to be a very joyful ... to help my students.” , The award will allow the 4th grade teacher at Tumwater ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017  Twist ... high-quality DNA synthesis, today announced that it raised an ... a total of $166 million. "It ... as we expand our reach and continue to deliver ... in multiple market segments," commented Emily M. Leproust, Ph.D., ...
(Date:3/27/2017)...   Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company ... the Company,s Chief Operating Officer, is scheduled to present a corporate ... 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 ... ... 24th Annual Future Leaders in Biotech Industry – Friday, April 7, ...
(Date:3/24/2017)... PORTLAND, Oregon and PUNE, India , March 24, 2017 ... in 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a ... expected to generate the highest revenue, and is projected to dominate the market during ... ... Allied Market Research Logo ...
Breaking Medicine Technology:
Cached News: